1. Apoptosis Metabolic Enzyme/Protease Immunology/Inflammation NF-κB Protein Tyrosine Kinase/RTK
  2. Lipoxygenase Apoptosis Reactive Oxygen Species (ROS) FAK
  3. LXG6403

LXG6403 是一种口服有效的不可逆 LOX 抑制剂 (IC50 = 1.3 μM)。LXG6403 对 LOX 的特异性比对 LOXL2 的特异性高约 3.5 倍,并且不抑制 LOXL1。LXG6403 抑制了 FAK 信号传导并诱导 ROS 生成和 DNA 损伤,引发 G1 期阻滞和在化疗耐药的三阴性乳腺癌 (TNBC) 细胞系中细胞凋亡 (apoptosis)。LXG6403 改变细胞外基质 (ECM) 和胶原结构,减少胶原交联和沉积从而增加药物的渗透率,降低肿瘤硬度。LXG6403 克服体内化疗耐药 TNBC PDX 的 Doxorubicin (HY-15142) 耐药性,可用于高硬度耐药肿瘤的研究。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

LXG6403

LXG6403 Chemical Structure

CAS No. : 315705-04-5

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
5 mg ¥1515
1-2 周
10 mg ¥2274
1-2 周
25 mg ¥4548
1-2 周
50 mg 询价 1-2 周
100 mg 询价 1-2 周
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Customer Review

查看 Lipoxygenase 亚型特异性产品:

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

LXG6403 is an orally active and irreversible LOX inhibitor (IC50 = 1.3 μM). LXG6403 is ~3.5-fold more specific for LOX than LOXL2 and does not inhibit LOXL1. LXG6403 inhibits FAK signaling and induces ROS generation and DNA damage, leading to G1 arrest and apoptosis in chemoresistant triple-negative breast cancer (TNBC) cell lines. LXG6403 alters the extracellular matrix (ECM) and collagen structure, reducing collagen cross-linking and deposition, thereby increasing drug penetration and reducing tumor stiffness. LXG6403 overcomes Doxorubicin (HY-15142) resistance in chemoresistant TNBC PDX in vivo and can be used to study high-stiffness resistant tumors[1].

体外研究
(In Vitro)

LXG6403 (Compound 9) 抑制细胞 LOX 活性,IC50 分别为 1.3 μM (MDA-MB-231 细胞)、1.43 Μm (HCC143 细胞)、4.14 μM (Hs-578-T 细胞) 和 3.0 μM (HCC1937 细胞)[1]

LXG6403 (0-10 μM) 可抑制 rLOX,rLOXL2,rLOX-CM 和 rLOXL2-CM活性,IC50 分别为 0.28 μM,0.95 μM,0.95 μM 和 2.82 μM,但不抑制 HEK293T 细胞中的 rLOXL1 (IC50 > 10 μM)[1]

LXG6403 (0-20 μM) 可抑制链霉蛋白酶介导的 LOX 降解[1]

LXG6403 (15 μM,48 小时) 可增强 TNBC 细胞、MDA-MB-231 和 HCC1143 在 3D 胶原 I 中对蒽环类药物 Doxorubicin (HY-15142A)、铂类药物 Cisplatin (HY-17394) 和紫杉烷类药物 Paclitaxel (HY-B0015) 的应答[1]

LXG6403 (9 天) 可降低类器官的活力和大小,并降低化疗药物如阿霉素、顺铂或紫杉醇的疗效[1]

LXG6403 (20 µM,48 小时) 可抑制高迁移率 MDA-MB-231 细胞的迁移能力[1]

LXG6403 (15 μM) 可减少胶原蛋白和纤连蛋白在细胞外基质 (ECM) 中的沉积并抑制其组装。在两种实验条件下,将 HFF-1 细胞在 ECM 生成过程中与 LXG6403 孵育,并将 HCC1143 细胞接种到 HFF-1 衍生的脱细胞 ECM 上,并在加入或不加入 LXG6403 的情况下进行培养[1]

LXG6403 可提高 Doxorubicin (HY-15142A) 在 3D 胶原蛋白 I 包埋的 TNBC 细胞系和 PDX 类器官中的渗透性[1]

LXG6403 在 MDA-MB-231 细胞中抑制脂氧合酶 (LOX),增强药物在 3D 培养中的渗透性,诱导活性氧 (ROS) 生成/DNA 损伤,并抑制黏着斑激酶 (FAK) 信号传导,导致三阴性乳腺癌 (TNBC) 细胞系和类器官的 G1 期停滞和凋亡[1]

LXG6403 (2.5-20 μM) 不会改变 MCF12A、HUVEC 和 HFF-1 细胞的细胞活力[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: MDA-MB-231 cells
Concentration: 20 μM
Incubation Time: 24 h, 48 h
Result: Increased γ-H2AX levels, cleaved caspase-3 and cleaved PARP levels, and decreased FAK phosphorylation.
体内研究
(In Vivo)

LXG6403 (Compound 9) (25-200 mg/kg,口服,5 天) 不会改变 BALB/c 小鼠的体重或血细胞计数,也不会引起器官损伤[1]

LXG6403 (50 mg/kg,口服,每日一次,24 天) 联合 Doxorubicin 治疗耐药性 TM01278 TNBC PDX 小鼠模型 (LOX 表达较高) 可降低纤维胶原含量/交联,从而增加药物渗透和活性氧 (ROS) 积累,抑制 FAK 信号传导,诱导 DNA 损伤、G1 期阻滞和细胞凋亡[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: TM01278 TNBC PDX mice model[1]
Dosage: 50 mg/kg
Administration: p.o., daily, 24 days
Result: Reduced tumor growth and tumor weight without changing body weight combined with Doxorubicin.
Reduced fibrillar collagen and insoluble collagen content combined with Doxorubicin.
Increased doxorubicin penetration in vivo, increased ROS accumulation (and DNA damage, further leading to FAK inhibition, induction of G1 arrest and apoptosis combined with Doxorubicin.
分子量

345.44

Formula

C15H15N5OS2

CAS 号
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料
参考文献
  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
LXG6403
目录号:
HY-171955
需求量: